UBS Maintains Buy on CRH, Lowers Price Target to $135

Benzinga Newsdesk www.benzinga.com Negative 52.4%

Neg 52.4% Neu 0% Pos 0%

UBS analyst Julian Radlinger maintains CRH (NYSE:CRH) with a Buy and lowers the price target from $147 to $135.

Comments

No comments yet. Be the first!